Sei Investments Co. Sells 17,535 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Sei Investments Co. decreased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 9.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 161,682 shares of the company's stock after selling 17,535 shares during the period. Sei Investments Co. owned approximately 0.13% of Vaxcyte worth $13,235,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Janus Henderson Group PLC raised its holdings in shares of Vaxcyte by 23.1% in the 3rd quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company's stock worth $1,247,954,000 after acquiring an additional 2,052,989 shares during the last quarter. RA Capital Management L.P. raised its stake in shares of Vaxcyte by 5.9% in the third quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company's stock worth $992,914,000 after purchasing an additional 485,436 shares during the last quarter. State Street Corp lifted its holdings in shares of Vaxcyte by 1.1% in the third quarter. State Street Corp now owns 3,405,743 shares of the company's stock valued at $389,174,000 after purchasing an additional 38,596 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Vaxcyte by 13.2% during the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company's stock valued at $315,162,000 after buying an additional 324,560 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Vaxcyte by 10.6% during the third quarter. Geode Capital Management LLC now owns 2,700,782 shares of the company's stock worth $308,675,000 after buying an additional 259,010 shares in the last quarter. 96.78% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on PCVX shares. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a report on Friday, December 20th. They set a "buy" rating and a $135.00 price objective on the stock. Guggenheim restated a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a report on Wednesday, March 12th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, February 26th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $147.50.

Vaxcyte Stock Performance

PCVX stock traded down $31.70 during mid-day trading on Monday, hitting $37.76. The company had a trading volume of 13,995,362 shares, compared to its average volume of 1,032,557. Vaxcyte, Inc. has a 12 month low of $30.29 and a 12 month high of $121.06. The stock's fifty day moving average price is $80.07 and its two-hundred day moving average price is $92.37. The firm has a market cap of $4.86 billion, a PE ratio of -8.21 and a beta of 1.02.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping analysts' consensus estimates of ($1.16) by $0.14. Equities analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Insider Buying and Selling at Vaxcyte

In related news, COO Jim Wassil sold 8,000 shares of the company's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total transaction of $669,280.00. Following the sale, the chief operating officer now directly owns 205,695 shares in the company, valued at approximately $17,208,443.70. This represents a 3.74 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the transaction, the director now owns 7,175 shares of the company's stock, valued at $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 46,250 shares of company stock worth $3,840,018 over the last ninety days. 3.10% of the stock is currently owned by company insiders.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.